| 生物活性 |
Theasaponin E1 is an orally active tea saponin that inhibits cancer cell proliferation by activating apoptosis, suppresses angiogenesis in ovarian cancer cells and HUVECs by reducing VEGF expression, upregulates ATM protein phosphorylation levels and PTEN protein expression in cancer cells, decreases Akt, mTOR, p70S6K, and 4E-BP1 protein phosphorylation levels, downregulates HIF-1α and NF-κB expression as well as the protein expression of Notch ligands Dll4 and Jagged1, and exerts neuroprotective effects by inhibiting acetylcholinesterase activity, activating α-secretase and neprilysin, reducing Aβ concentration, and inhibiting β-secretase and γ-secretase activities; moreover, Theasaponin E1 exhibits toxic effects and quinone reductase-inducing activity in cancer cells, inhibits tumor growth in vivo, induces ferroptosis in Fushou via synergistic disruption of cholesterol homeostasis and sphingolipid metabolism, possesses anti-biofilm activity against Candida albicans, and can be used for research on ovarian cancer, obesity, Alzheimer's disease, and fungal infections. |
体外研究 (In Vitro) |
Theasaponin E1 (1-5 μM; 24 h) 可在体外强效抑制 OVCAR-3 (IC50 = 3.5 μM) 和 A2780/CP70 (IC50 = 2.8 μM) 细胞的生长,24 h 时对正常卵巢 IOSE-364 细胞的细胞毒性较低 (24 h 时 IC50 > 5 μM)。 Theasaponin E1 (1-4 μM; 24 h) 通过内源性和外源性凋亡通路诱导 OVCAR-3 细胞发生凋亡,上调 DNA 损伤标志物水平。 Theasaponin E1 (1-4 μM; 24 h) 可通过升高 p-Chk2、p21、p-cdc2 (Tyr15) 及 Cyclin B1,轻度诱导 OVCAR-3 细胞发生 G2/M 期细胞周期阻滞。 Theasaponin E1 (1-4 μM; 24 h) 抑制 OVCAR-3 细胞的迁移,降低细胞的 VEGF 分泌。 Theasaponin E1 (1-4 μM; 24 h) 上调 OVCAR-3 细胞中的 ATM 蛋白磷酸化水平、PTEN 蛋白表达量,降低 Akt、mTOR、p70S6K 及 4E-BP1 蛋白磷酸化水平,下调 HIF-1α、VEGF 蛋白表达。 Theasaponin E1 (1-4 μM; 24 h) 可降低 NICD、Dll4 和 Jagged1 的蛋白表达,抑制 OVCAR-3 细胞中 Notch1 信号通路。 Theasaponin E1 (1-25 μg/mL; 4 h) 可强效抑制人脐静脉内皮细胞 (HUVECs) 的毛细血管管形成。 Theasaponin E1 (1-10 μg/mL; 24 h) 可剂量依赖性地抑制 HCC-1428、SNU-1005、SNU-432 以及 SNU-719 的增殖。 Theasaponin E1 (5-25 μg/mL; 24 h) 抑制 HUVECs 中 VEGF 受体复合物组分 VEGFR-2、PI3 K、β-Catenin 和 VE-Cadherin 的表达及相互作用,下调细胞中 VEGFR-2、PI3K、β-Catenin、VE-钙黏蛋白、Akt 和 NF-κB 的 mRNA 表达。 Theasaponin E1 (1-25 μg/mL; 48 h) 抑制分化中的 3T3-L1 脂肪细胞内脂滴的积累。 Theasaponin E1 (5-20 μg/mL; 10 min) 抑制乙酰胆碱酯酶活性。 Theasaponin E1 (5-20 μg/mL; 24 h) 在 SweAPP N2a 细胞中激活 α-分泌酶 (ADAM10) 和脑啡肽酶,抑制 β-分泌酶和 γ-分泌酶亚基 (PS1、NCT),上调 ADAM10 和脑啡肽酶的 mRNA 和蛋白表达,下调 BACE1、PS1、NCT 的 mRNA 和蛋白表达。 Theasaponin E1 (5-20 μg/mL; 24 h) 在 SweAPP N2a 细胞中可剂量依赖性降低 Aβ 肽和 APP 水平。 Theasaponin E1 (3.55-12 mg/L; 48-96 h) 对福寿螺成螺具有浓度和时间依赖性的杀螺活性,其 96 h LC50 为 5.97 mg/L,96 h LC20 为 4.32 mg/L。 Theasaponin E1 (4.32 mg/L; 24 h) 可诱导福寿螺软组织中胆固醇稳态、膜完整性通路及铁死亡的失调,诱导福寿螺血细胞的细胞死亡水平升高,破坏福寿螺血细胞的细胞骨架结构并改变其细胞形态,引发代谢重编程,包括增强脂肪酰基周转、氧化脂质重塑以及解毒通路的激活。 Theasaponin E1 (4.32 mg/L; 24 h) 可上调福寿螺血细胞中细胞凋亡、鞘脂代谢及铁死亡相关基因的表达,同时下调 CTSL 的表达。 Theasaponin E1 (4.32 mg/L; 24 h) 可破坏福寿螺血细胞的鞘脂稳态,诱导质膜破裂,损伤溶酶体功能,引发铁过载与氧化应激,诱导福寿螺的透明细胞和无颗粒细胞发生严重的超微结构损伤。 Theasaponin E1 (0-400 μM; 1.5 h) 抑制白色念珠菌 ATCC 10231 对聚苯乙烯表面的黏附,其 IC50 为 33.64 μM。 Theasaponin E1 (0-400 μM; 24 h) 可浓度依赖性地抑制白假丝酵母菌 ATCC 10231 的早期生物膜形成,其 80%抑制浓度 (BIC80) 为 71.96 μM,清除白假丝酵母菌 ATCC 10231 的成熟生物膜,其 BEC80 为 234.75 μM。 Theasaponin E1 (25-100 μM; 1.5 h for adherent cells, 24 h for mature biofilms) 可降低白色念珠菌 ATCC 10231 的细胞表面疏水性,降低白色念珠菌 ATCC 10231 在黏附态和成熟生物膜态下的胞外磷脂酶活性。 Theasaponin E1 (100 μM; 1.5 h) 可显著下调白假丝酵母菌 ATCC 10231 中多个毒力相关基因的表达,包括与黏附、菌丝发育及信号通路相关的基因。 Theasaponin E1 (过夜) 对人 K562 和 HL-60 肿瘤细胞系表现出细胞毒活性,其 IC50 值分别为 17.9 μg/mL 和 13.7 μg/mL。 Theasaponin E1 (4-20 μg/mL) 在 Hepa 1c1c7 野生型肝癌细胞中表现出显著的醌还原酶诱导活性,在 4 μg/mL 时诱导率为 4.2 (57.0% cell viability),在 20 μg/mL 时诱导率为 4.4 (3.3% cell viability)。 Theasaponin E1 (5-40 μM; 24-72 h) 可剂量依赖性地抑制源自 A2780/CP70 和 OVCAR-3 细胞系的 ALDH 阳性卵巢癌干细胞样细胞的活力以及单细胞球形成能力。
Cell Viability Assay
| Cell Line: |
OVCAR-3 cells, A2780/CP70 cells, IOSE-364 cells |
| Concentration: |
0, 1, 2, 3, 4, 5 μM |
| Incubation Time: |
24 h |
| Result: |
Inhibited OVCAR-3 and A2780/CP70 cell growth in a concentration-dependent manner, with IC50 values of 3.5 μM (OVCAR-3) and 2.8 μM (A2780/CP70) at 24 h. Killed approximately 80% of OVCAR-3 cells and 98% of A2780/CP70 cells at 4 μM. Exhibited an IC50 value of more than 5 μM for normal IOSE-364 cells at 24 h, with no obvious inhibitory effect on IOSE-364 cells at 4 μM. |
Apoptosis Analysis
| Cell Line: |
human platinum-resistant ovarian cancer OVCAR-3 cells |
| Concentration: |
0, 1, 2, 3, 4 μM |
| Incubation Time: |
24 h |
| Result: |
Induced apoptotic morphology (fragmented/condensed nuclei) observed via Hoechst 33342 staining. Increased total early and late apoptotic cells from 10.80% to 74.18% and decreased live cells from 84.92% to 21.48% in a concentration-dependent manner via flow cytometry. Markedly increased protein levels of cleaved-Caspase-3, cleaved-Caspase-7, cleaved-PARP, phospho-Histone H2A.X (Ser139), proapoptotic Bax, Cytochrome C, pro-Caspase-9, cleaved-Caspase-9, DR4, FADD, and cleaved-Caspase-8. Reduced antiapoptotic Bcl-xL expression and slightly increased pro-Caspase-8 expression, with no obvious effect on pro-Caspase-3 or pro-Caspase-7. |
Cell Cycle Analysis
| Cell Line: |
OVCAR-3 cells |
| Concentration: |
0, 1, 2, 3, 4 μM |
| Incubation Time: |
24 h |
| Result: |
Increased the population of cells in G2/M phase from 14.70% to 21.96% via flow cytometry. Significantly increased protein levels of p-Chk2, p21, and p-cdc2 (Tyr15), and downregulated Cyclin B1 protein expression via Western blot. |
Cell Migration Assay
| Cell Line: |
OVCAR-3 cells |
| Concentration: |
0-4 μM |
| Incubation Time: |
24 h |
| Result: |
Increased the relative space between scratch edges from 57.50% to 100.00% in a concentration-dependent manner at 24 h, indicating inhibited migration. |
Western Blot Analysis
| Cell Line: |
human platinum-resistant ovarian cancer OVCAR-3 cells |
| Concentration: |
0-4 μM (alone); 2 μM (combined with 100 nM wortmannin) |
| Incubation Time: |
24 h |
| Result: |
Significantly increased phosphorylation of ATM (Ser1981) and PTEN protein expression, decreased phosphorylation of Akt (Ser473), mTOR (Ser2448), p70S6K (Thr421/Ser424), and 4E-BP1 (Ser65/Thr70), and downregulated HIF-1α protein expression when used alone. Enhanced the inhibitory effect on p-Akt, HIF-1α protein expression, and VEGF secretion when combined with 100 nM wortmannin compared to single treatment. |
RT-PCR
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
5 μg/mL, 10 μg/mL, 25 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Downregulated mRNA expression levels of VEGFR-2, PI3 K, β-Catenin, VE-Cadherin, Akt, and NF-κB in a dose-dependent manner. Showed the most pronounced reduction of mRNA expression at 25 μg/mL. |
ELISA Assay
| Cell Line: |
SweAPP N2a mouse neuroblastoma cells |
| Concentration: |
5-20 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Reduced Aβ peptide levels in a dose-dependent manner, decreasing levels to ~100 pg/mL from a control level of ~180 pg/mL at 20 μg/mL. Reduced APP levels in a dose-dependent manner, decreasing levels to ~250 pg/mL from a control level of ~380 pg/mL at 20 μg/mL. |
Real Time qPCR
| Cell Line: |
Candida albicans ATCC 10231 |
| Concentration: |
100 μM |
| Incubation Time: |
1.5 h |
| Result: |
Significantly downregulated the expression of adhesion-related genes (ALS1, ALS3, HWP1, EAP1), hyphal development-related genes (UME6, EED1, HGC1, HYR1), signaling pathway genes (RAS1, CPH1, TPK2, EFG1), and secreted hydrolase genes (SAP5, PLB1, PLB2) relative to untreated controls. |
|